Matthew R Zibelman Selected Research

Matthew R Zibelman Research Topics

5	Neoplasms (Cancer) 04/2024 - 01/2019
5	Carcinoma (Carcinomatosis) 01/2023 - 01/2019
3	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 10/2022
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 10/2018
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 01/2019
1	Bites and Stings (Sting) 01/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Tuberous Sclerosis (Bourneville's Disease) 09/2020
1	Angiomyolipoma 09/2020
1	Pathologic Complete Response 01/2020

5	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2019
4	Immune Checkpoint InhibitorsIBA 01/2023 - 10/2018
2	AndrogensIBA 03/2024 - 10/2022
2	Hormones (Hormone)IBA 03/2024 - 10/2022
2	bicalutamide (Casodex)FDA LinkGeneric 03/2024 - 10/2022
2	orteronelIBA 03/2024 - 10/2022
2	LigandsIBA 01/2023 - 01/2023
2	pembrolizumabIBA 01/2023 - 01/2023
1	Fatty Acids (Saturated Fatty Acids)IBA 04/2024
1	Phosphates (Orthophosphate)IBA 04/2024
1	PentosesIBA 04/2024
1	Prostate-Specific Antigen (Semenogelase)IBA 03/2024
1	enfortumab vedotinIBA 01/2023
1	guadecitabineIBA 01/2023
1	IpilimumabIBA 01/2023
1	Chimeric Antigen ReceptorsIBA 01/2023
1	NivolumabIBA 01/2023
1	Axitinib (AG 013736)IBA 01/2023
1	AntibodiesIBA 01/2023
1	AntigensIBA 01/2023
1	atezolizumabIBA 01/2023
1	PlatinumIBA 01/2023
1	Everolimus FDA Link 09/2020